Key Takeaways
- Clinical Bottom Line
- The Pathogenic Triad of IBD
Clinical Bottom Line
| Pathogenic Vector | Mechanism in IBD | Therapeutic Target |
|---|---|---|
| Genetic Susceptibility | NOD2/CARD15 mutations impairing bacterial recognition. | Currently non-targetable; prognostic for stricturing Crohn’s. |
| Epithelial Barrier Defect | Loss of tight junctions allowing luminal antigens to penetrate the lamina propria. | S1P receptor modulators and mucosal healing targets. |
| Aberrant Immune Response | Overactive Th1 (CD) or Th2 (UC) cytokine cascades (TNF, IL-12/23). | Monoclonal antibodies (Infliximab, Ustekinumab, Risankizumab). |
The Pathogenic Triad of IBD
Inflammatory Bowel Disease is fundamentally an inappropriate, perpetual immune response to commensal gut flora occurring in a genetically susceptible host. It is not an autoimmune attack against native tissue, but rather a catastrophic failure of the gut’s tolerance mechanisms to innocent resident bacteria.
Epithelial Permeability and Cytokine Storm
The pathogenesis begins with a breakdown of the intestinal epithelial barrier. When commensal bacteria breach this leaky barrier and enter the lamina propria, antigen-presenting cells (dendritic cells, macrophages) mistakenly identify them as hostile pathogens. This triggers a massive, localized cytokine storm—driven heavily by Tumor Necrosis Factor (TNF-alpha) and Interleukins (IL-12, IL-23). These inflammatory cytokines recruit devastating effector T-cells to the mucosa, leading to aggressive tissue ulceration and the macroscopic manifestations of the disease.
Clinical guidelines summarized by the Gastroscholar Research Team. Last updated: 2026. This article is intended for physicians.
